Key Highlights
- Lisata Therapeutics shares fell 36% to close at $2.24, their lowest point in almost half a year.
- The decline follows a breach of contract by Kuva Labs.
- Approximately 6.1 million shares, representing 66.8% of the company, were tendered by the July 20 deadline.
- Kuva failed to finalize the acquisition due to financing difficulties.
Lisata Therapeutics (NASDAQ: LSTA) shares closed down 36% at $2.24, reaching their lowest point in almost half a year, following a breach of contract by Kuva Labs.
What Happened
Approximately 6.1 million shares, representing 66.8% of the company, were tendered by the July 20 deadline, but Kuva failed to finalize the acquisition due to financing difficulties.
Lisata confirmed that the minimum acceptance threshold was met, yet payment was never delivered.
Market Reaction
Shares fell 36% to a nearly six-month low as investors reacted to the collapse of the tender offer despite the threshold having been satisfied.
Outlook
The company is now exploring potential legal recourse against Kuva for failing to honor the purchase agreement.
Why did Lisata Therapeutics shares fall 36%?
Shares fell after Kuva Labs breached its contract, failing to finalize its tender offer acquisition despite the minimum acceptance threshold being met.
How many shares were tendered by the deadline?
Approximately 6.1 million shares, representing 66.8% of the company, were tendered by the July 20 deadline.
What is Lisata Therapeutics doing in response?
The company is exploring potential legal recourse against Kuva Labs for failing to honor the purchase agreement.






Please wait processing your request...